- Report
- May 2023
- 60 Pages
Global
From €624EUR$695USD£531GBP
- Report
- October 2021
- 24 Pages
Global
From €1751EUR$1,950USD£1,491GBP
- Report
- October 2021
- 34 Pages
Global
From €624EUR$695USD£531GBP
- Report
- April 2023
- 116 Pages
Global
From €4040EUR$4,500USD£3,441GBP
- Report
- January 2023
- 293 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- January 2023
- 114 Pages
Middle East, Africa, Global Middle East, Africa, Global
From €1347EUR$1,500USD£1,147GBP
From €1347EUR$1,500USD£1,147GBP
- Report
- January 2023
- 110 Pages
Global, Europe
From €1347EUR$1,500USD£1,147GBP
From €1347EUR$1,500USD£1,147GBP
- Report
- March 2022
- 327 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- March 2022
- 129 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- June 2023
- 120 Pages
Global
From €3500EUR$4,176USD£3,085GBP
- Report
- November 2023
- 98 Pages
Global
From €1347EUR$1,500USD£1,147GBP
- Book
- June 2024
- 224 Pages

The Real World Evidence (RWE) market within the context of E-Healthcare is a rapidly growing sector. It is a form of evidence-based medicine that uses data from real-world sources such as patient records, claims data, and observational studies to inform healthcare decisions. RWE can be used to assess the safety and effectiveness of treatments, identify new indications for existing treatments, and inform healthcare policy. It can also be used to assess the cost-effectiveness of treatments and to identify potential areas of improvement in healthcare delivery.
RWE is increasingly being used by healthcare providers, payers, and pharmaceutical companies to inform their decisions. It is also being used by researchers to gain insights into the effectiveness of treatments and to identify potential areas of improvement in healthcare delivery.
Some companies in the RWE market include IBM Watson Health, Optum, Flatiron Health, and Evidation Health. Show Less Read more